nivolumab and pembrolizumab for lung cancer

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
nivolumab and pembrolizumab for lung cancer	1.69	0.2	3348	98	43
nivolumab	1.45	1	2341	13	9
and	0.06	0.3	7857	38	3
pembrolizumab	1.78	0.2	194	95	13
for	0.97	0.8	7674	59	3
lung	1.39	0.1	6633	26	4
cancer	1.16	1	6881	74	6

Keyword	CPC	PCC	Volume	Score
nivolumab and pembrolizumab for lung cancer	0.53	0.5	5242	78
pembrolizumab for lung cancer	0.09	1	5779	74
nivolumab and pembrolizumab combination	0.01	0.8	8323	49
nivolumab and pembrolizumab for melanoma	1.67	0.8	1310	63
nivolumab and pembrolizumab for mesothelioma	1.92	0.6	2414	95
nivolumab for lung cancer	0.7	1	7070	88
pembrolizumab lung cancer fda	0.35	0.5	2130	64
pembrolizumab chemotherapy lung cancer	1.38	0.5	4200	7
pembrolizumab single agent lung cancer	1.62	0.9	5961	97
nejm pembrolizumab lung cancer	0.56	0.8	4637	9
nivolumab pembrolizumab and atezolizumab	1	0.2	6980	2
pembrolizumab adjuvant lung cancer	1.89	0.2	5726	58
neoadjuvant pembrolizumab lung cancer	0.99	0.7	2607	78
pembrolizumab small cell lung cancer	0.21	1	6085	65
pembrolizumab metastatic lung cancer	0.25	0.1	4800	59
pembrolizumab versus nivolumab for melanoma	1.7	0.9	9719	39
pembrolizumab non small cell lung cancer nejm	0.01	0.6	6734	34
pembrolizumab lung cancer fda approval	1.98	0.1	6374	70
lung cancer chemo drug nivolumab	1.25	0.3	4028	67
pembrolizumab compared to nivolumab	1.09	0.8	2589	29
pembrolizumab keynote metastatic lung cancer	0.51	0.6	6466	90
pembrolizumab vs nivolumab mechanism	0.16	0.7	7514	91